Drugs / BMS-986504
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06883747 | Apr 2025 → Sep 2026 overdue | glioblastoma | Nader Sanai | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07532902 | Apr 2026 → Apr 2029 expected | diffused pleural mesothelioma, gastroesophageal cancer, urothelial carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07077434 | Oct 2025 → Jan 2027 expected | cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT06672523 | Mar 2025 → Oct 2027 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07594626 | Dec 2027 → Dec 2030 expected | biliary tract cancer, carcinoma of esophagus, colon carcinoma, metastatic carcinoma | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07549022 | Aug 2026 → Apr 2028 expected | malignant peripheral nerve sheath tumor | Ankit Mangla, MD | Not yet recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07492680 | Jul 2026 → Aug 2028 expected | cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2 | NCT07602946 | May 2026 → Jul 2027 expected | mesothelioma | University of Southampton | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07283705 | Apr 2026 → Oct 2029 expected | pancreas disorder | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT07063745 Comparator | Jan 2026 → Aug 2031 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07063745 ↗ |
| Known as | MTA-cooperative PRMT5 Inhibitor BMS-986504 | “MTA-cooperative PRMT5 Inhibitor BMS-986504” NCT07594626 ↗ |
| Known as | Navlimetostat | “Navlimetostat (BMS-986504)” NCT07063745 ↗ |
| Action | Inhibit | “MTA cooperative PRMT5 inhibitor” NCT06883747 ↗ |
| Route | Oral | “single oral dose of radiolabeled \[14C\]-BMS-986504” NCT06672523 ↗ |
| Target | PRMT5 | “MTA cooperative PRMT5 inhibitor” NCT06883747 ↗ |